Ipratropium Bromide(Sch 1000)

Molecular Weight (MW)	412.37
Formula	C20H30BrNO3
CAS No.	22254-24-6
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 83 mg/mL (201.3 mM)
Water: 83 mg/mL (201.3 mM)
Ethanol: 83 mg/mL (201.3 mM)
Other info	Chemical Name: [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;bromide InChi Key: LHLMOSXCXGLMMN-CLTUNHJMSA-M InChi Code: InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18?,19?,21?; SMILES Code: O=C(OC1C[C@]([N+]2(C)C(C)C)([H])CC[C@]2([H])C1)C(C3=CC=CC=C3)CO.[Br-]
Synonyms	Sch-1000; ipratropium bromide, Sch 1000; Sch1000; trade names: Atrovent, Apovent, Ipraxa, Rinatec

Molecular Weight (MW)

412.37

Formula

C20H30BrNO3

CAS No.

22254-24-6

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 83 mg/mL (201.3 mM)

Water: 83 mg/mL (201.3 mM)

Ethanol: 83 mg/mL (201.3 mM)

Other info

Chemical Name: [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;bromide
InChi Key: LHLMOSXCXGLMMN-CLTUNHJMSA-M
InChi Code: InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18?,19?,21?;
SMILES Code: O=C(OC1C[C@]([N+]2(C)C(C)C)([H])CC[C@]2([H])C1)C(C3=CC=CC=C3)CO.[Br-]

Synonyms

Sch-1000; ipratropium bromide, Sch 1000; Sch1000; trade names: Atrovent, Apovent, Ipraxa, Rinatec

In Vitro	In vitro activity: Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry. Cell Assay: Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine. Target: mAChR Ipratropium bromide, a nonselective muscarinic antagonist, is widely prescribed for the treatment of chronic obstructive pulmonary disease (COPD).
In Vivo	Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse.
Animal model	Horses and pigs
Formulation & Dosage	2400 mg/horse
References	Eur J Pharmacol. 2010 Nov 25;647(1-3):178-87; Equine Vet J. 1999 Jan;31(1):20-4.

In Vitro

In vitro activity: Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry.

Cell Assay: Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine. Target: mAChR Ipratropium bromide, a nonselective muscarinic antagonist, is widely prescribed for the treatment of chronic obstructive pulmonary disease (COPD).

In Vivo

Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse.

Animal model

Horses and pigs

Formulation & Dosage

2400 mg/horse

References

Eur J Pharmacol. 2010 Nov 25;647(1-3):178-87; Equine Vet J. 1999 Jan;31(1):20-4.

CAS NO:	22254-24-6
规格:	≥98%

包装	价格(元)
50mg	询价
100mg	询价
250mg	询价
500mg	询价
1g	询价
2g	询价